| Name | (2R)-3-(3,4-Dihydroxyphenyl)-2-({(2E)-3-[2-(3,4-dihydroxyphenyl)- 7-hydroxy-1-benzofuran-4-yl]-2-propenoyl}oxy)propanoic acid |
|---|---|
| Synonyms |
(2R)-3-(3,4-Dihydroxyphenyl)-2-({(2E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-1-benzofuran-4-yl]prop-2-enoyl}oxy)propanoic acid
(2R)-3-(3,4-Dihydroxyphenyl)-2-({(2E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-1-benzofuran-4-yl]-2-propenoyl}oxy)propanoic acid Benzenepropanoic acid, α-[[(2E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-4-benzofuranyl]-1-oxo-2-propen-1-yl]oxy]-3,4-dihydroxy-, (αR)- Salvianolic acid C |
| Description | Salvianolic acid C is a noncompetitive Cytochrome P4502C8 (CYP2C8) inhibitor and a moderate mixed inhibitor of Cytochrome P45022J2 (CYP2J2), with Kis of 4.82 μM and 5.75 μM for CYP2C8 and CYP2J2, respectively. |
|---|---|
| Related Catalog | |
| Target |
CYP2C8:4.82 μM (Ki) CYP2J2:5.75 μM (Ki) |
| In Vitro | Salvianolic acid C is a noncompetitive CYP2C8 inhibitor and a moderate mixed inhibitor of CYP2J2, with Kis of 4.82, 5.75 μM for CYP2C8 and CYP2J2, respectively[1]. 1 and 5 μM Salvianolic acid C (SalC) could significantly inhibit the NO production induced by LPS. Salvianolic acid C decreases the expression of iNOS significantly. Salvianolic acid C inhibits LPS-induced TNF-α, IL-1β, IL-6 and IL-10 overproduction. Salvianolic acid C inhibits LPS-induced NF‑κB activation. Salvianolic acid C also increases the expression of Nrf2 and HO-1 in BV2 microglial cells[2]. |
| In Vivo | Salvianolic acid C (20 mg/kg) treatment could significantly decrease the escape latency. In addition, SalC (10 and 20 mg/kg) treatment significantly increase the platform crossing number compared with the LPS model group. Systemic administration of Salvianolic acid C down regulates the brain TNF-α, IL-1β and IL-6 levels compared with the model group. The iNOS and COX-2 levels in rat brain cortex and hippocampus are higher than that in the control group, while Salvianolic acid C treatment significantly down regulates the cortex and hippocampus regions. Salvianolic acid C (5, 10 and 20 mg/kg) treatment dose-dependently increases the p-AMPK, Nrf2, HO-1 and NQO1 levels in rat brain cortex and hippocampus[2]. |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 844.2±65.0 °C at 760 mmHg |
| Molecular Formula | C26H20O10 |
| Molecular Weight | 492.431 |
| Flash Point | 464.4±34.3 °C |
| Exact Mass | 492.105652 |
| PSA | 177.89000 |
| LogP | 3.12 |
| Vapour Pressure | 0.0±3.3 mmHg at 25°C |
| Index of Refraction | 1.752 |
| Storage condition | 2-8C |